ArticleDiabetes, metabolic syndrome and obesity : targets and therapy2026
Association Between
Article in Diabetes, metabolic syndrome and obesity : targets and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Diabetic kidney disease (DKD) is one of the major complications of type 2 diabetes mellitus (T2DM), which is common worldwide. Its pathogenesis involves various mechanisms: Notably, overactivation of the renin-angiotensin-aldosterone system (RAAS) and genetic susceptibility. Although RAAS gene polymorphisms have been widely studied, the results vary across various ethnicities. In this study, we investigated the association between the Patients and Methods: A case-control study was conducted from November 2022 to November 2024 at the University Medical Center at Ho Chi Minh City and Nhan Dan Gia Dinh Hospital. The case group included patients with T2DM and confirmed DKD, while the control group comprised patients with T2DM without DKD. The participants were matched by age and sex. Clinical, biochemical, and genetic data were collected, including those on ACE I/D polymorphisms. Results: A total of 578 patients were enrolled, with 289 in the case group and 289 in the control group. The participants had a mean age of 63.4 ± 10.8 years, of which 41.3% were male. Compared with the controls, patients with DKD experienced longer T2DM durations and higher rates of hypertension, heart failure, and chronic anemia, higher HbA1c levels, and lipid profiles ( Conclusion: Among the Vietnamese Kinh population, a significant association was found between the ACE I/D polymorphism and DKD in patients with T2DM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.